Precision Cancer Therapy in Rare Cancers
ConditionRare Malignant Neoplasm
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age16-99
SponsorOslo University Hospital
About this trial
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.
In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Eligibility criteria
Qualifiers
ECOG 0-2,
identified biomarker,
reasonable biochemistry
Disqualifiers
ECOG 3-5
serious other diseases
Trial design
Treatments tested in this trial
- Imatinib
- Trametinib
- Dabrafenib
Treatment groups
96 Participants
are divided into 1 treatment groupSponsors and collaborators
Oslo University Hospital
Lead sponsor
Helse Stavanger HF
Collaborator
University Hospital of North Norway
Collaborator
StOlavs Hospital
Collaborator
Nordlandssykehuset HF
Collaborator
Helse Nord-Trøndelag HF
Collaborator
Sorlandet Hospital HF
Collaborator
Møre og Romsdal Hospital Trust
Collaborator
The Hospital of Vestfold
Collaborator
Helse Fonna
Collaborator
Haukeland University Hospital
Collaborator
Sykehuset Ostfold
Collaborator
Helse Forde
Collaborator
Sykehuset Innlandet HF
Collaborator
Source ClinicalTrials.gov